GRTX Stock Price, Galera Therapeutics Inc Quote, Chart

Market Summary

USD0.190.00

Delayed

0.00%

GRTX Alerts

1 major insider buys recently.

GRTX Stock Price

View Fullscreen

GRTX RSI Chart

GRTX Valuation

Market Cap

10.3M

Price/Earnings (Trailing)

-0.23

EV/EBITDA

0.06

Price/Free Cashflow

-0.27

MarketCap/EBT

-0.17

GRTX Price/Sales (Trailing)

GRTX Profitability

Return on Equity

33.97%

Return on Assets

-232.83%

Free Cashflow Yield

-368.01%

GRTX Fundamentals

GRTX Earnings

Earnings (TTM)

-45.8M

Earnings Growth (Yr)

75.26%

Earnings Growth (Qtr)

21.59%

Breaking Down GRTX Revenue

Last 7 days

5.6%

Last 30 days

-5%

Trailing 12 Months

-93.7%

How does GRTX drawdown profile look like?

GRTX Financial Health

Current Ratio

7.54

GRTX Investor Care

Shares Dilution (1Y)

26.77%

Diluted EPS (TTM)

-0.43

Tracking the Latest Insider Buys and Sells of Galera Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	schneid yair	bought	19,395	0.193957	100,000	-
Apr 18, 2024	schneid yair	bought	107,395	0.19612	547,600	-
Apr 17, 2024	schneid yair	bought	403,185	0.222182	1,814,660	-
Mar 28, 2024	altamont pharmaceutical holdings, llc	sold	-101,120	0.1459	-693,076	-
Mar 27, 2024	altamont pharmaceutical holdings, llc	sold	-52,146	0.1699	-306,924	-
Mar 26, 2024	altamont pharmaceutical holdings, llc	sold	-393,000	0.1965	-2,000,000	-
Mar 25, 2024	altamont pharmaceutical holdings, llc	sold	-170,742	0.2189	-780,000	-
Mar 22, 2024	altamont pharmaceutical holdings, llc	sold	-4,600	0.23	-20,000	-
Feb 08, 2024	schneid yair	bought	25,650	0.171	150,000	-
Feb 07, 2024	schneid yair	bought	30,185	0.172486	175,000	-

Which funds bought or sold GRTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-1,659	-	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-575	14,919	-%
May 15, 2024	MORGAN STANLEY	reduced	-0.11	-16.00	396	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-72.00	-	-%
May 15, 2024	Kestra Advisory Services, LLC	reduced	-9.79	-683	4,515	-%
May 15, 2024	Atom Investors LP	new	-	49,869	49,869	0.01%
May 15, 2024	Sofinnova Investments, Inc.	sold off	-100	-448,372	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	1,700	1,700	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	10,728	10,728	-%
May 15, 2024	Royal Bank of Canada	reduced	-1.18	-	5,000	-%

Are Funds Buying or Selling GRTX?

Are funds buying GRTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GRTX

No. of Funds

GRTX Alerts

1 major insider buys recently.

Unveiling Galera Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 16, 2024	soffer rochel	899%	5,928,137	SC 13G
May 16, 2024	schneid yair	19.90%	10,823,610	SC 13G/A
May 01, 2024	schneid yair	19.90%	10,823,610	SC 13G/A
Apr 16, 2024	alpha pharma investments llc	5.05%	11	SC 13G
Apr 03, 2024	altamont pharmaceutical holdings, llc	0%	0	SC 13G/A
Feb 20, 2024	sofinnova venture partners ix, l.p.	10.0%	0	SC 13D/A
Feb 14, 2024	sectoral asset management inc	0%	0	SC 13G/A
Jan 17, 2024	schneid yair	073%	7,110,801	SC 13G
Jan 02, 2024	gsa capital partners llp	156%	3,892,561	SC 13G
Dec 04, 2023	blackstone holdings i/ii gp l.l.c.	1.0%	542,555	SC 13D/A

Recent SEC filings of Galera Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	3	Insider Trading
May 16, 2024	SC 13G	Major Ownership Report
May 16, 2024	SC 13G/A	Major Ownership Report
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 03, 2024	8-A12B	8-A12B
May 03, 2024	8-K	Current Report
May 01, 2024	SC 13G/A	Major Ownership Report
May 01, 2024	4/A	Insider Trading
Apr 16, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Galera Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Galera Therapeutics Inc News

Latest updates

Galera Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-24.8%	20.00	26.00	38.00	48.00	60.00	44.00	51.00	61.00	71.00	83.00	99.00	115	70.00	84.00	98.00	114	131	123	80.00	88.00
Current Assets	-29.8%	15.00	22.00	31.00	42.00	54.00	39.00	45.00	55.00	65.00	77.00	93.00	109	64.00	78.00	92.00	108	125	118	72.00	84.00
Cash Equivalents	-26.2%	13.00	18.00	24.00	24.00	26.00	4.00	13.00	17.00	20.00	20.00	18.00	38.00	14.00	16.00	15.00	16.00	22.00	18.00	16.00	15.00
Net PPE	-12.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-1.9%	154	157	164	163	157	153	148	144	142	141	142	141	81.00	78.00	73.00	74.00	78.00	54.00	52.00	27.00
Current Liabilities	-59.4%	2.00	5.00	13.00	14.00	13.00	13.00	12.00	11.00	11.00	13.00	16.00	17.00	16.00	14.00	11.00	12.00	13.00	10.00	9.00	6.00
Shareholder's Equity	-2.7%	-134	-131	-	-	-97.61	-109	-	-	-	-58.00	-	-	-	6.00	25.00	40.00	53.00	70.00	-	-
Retained Earnings	-1.0%	-441	-437	-431	-416	-396	-378	-362	-346	-331	-316	-299	-276	-254	-235	-215	-198	-179	-161	-144	-104
Additional Paid-In Capital	0.3%	307	306	305	302	298	269	265	263	261	258	256	251	244	242	240	238	232	231	-	-
Shares Outstanding	0%	54.00	54.00	54.00	44.00	43.00	29.00	27.00	27.00	27.00	26.00	26.00	25.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	130	-	-	-	32.00	-	-	-	162	-	-	-	112	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	51.7%	-4,791	-9,915	-12,521	-10,746	-11,666	-13,945	-9,210	-8,886	-11,385	-17,446	-18,404	-16,805	-15,303	-16,450	-15,284	-15,411	-12,392	-15,276	-12,901	-9,555	-8,929
Share Based Compensation	-26.3%	875	1,187	1,390	1,525	1,458	1,736	1,750	1,830	1,848	1,959	1,870	1,611	1,791	1,368	1,505	1,453	1,210	806	520	565	499
Cashflow From Investing	-100.0%	-	3,975	10,464	7,549	5,305	2,779	4,604	6,615	9,996	19,651	-43,041	15,745	12,883	16,858	14,410	9,674	-4,395	-41,790	12,770	-1,401	2,596
Cashflow From Financing	100.0%	-	-232	2,134	1,812	27,782	2,702	10.00	2.00	1,175	22.00	40,612	25,838	235	232	224	41.00	20,009	59,703	-345	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GRTX Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 1,488	$ 7,272
General and administrative	3,089	6,609
Loss from operations	(4,577)	(13,881)
Other income (expenses):
Interest income	196	395
Interest expense	0	(4,223)
Foreign currency loss	0	(1)
Net loss	$ (4,381)	$ (17,710)
Net loss per share of common stock, basic	$ (0.08)	$ (0.5)
Net loss per share of common stock, diluted	$ (0.08)	$ (0.5)
Weighted-average shares of common stock outstanding, basic	54,392,170	35,196,134
Weighted-average shares of common stock outstanding, diluted	54,392,170	35,196,134

GRTX Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 13,466	$ 18,257
Prepaid expenses and other current assets	1,720	3,372
Total current assets	15,186	21,629
Property and equipment, net	62	71
Acquired intangible asset	2,258	2,258
Goodwill	881	881
Right-of-use lease assets	1,174	1,212
Other assets	90	90
Total assets	19,651	26,141
Current liabilities:
Accounts payable	1,046	1,375
Accrued expenses	831	3,449
Lease liabilities	136	133
Total current liabilities	2,013	4,957
Royalty purchase liability	151,049	151,049
Lease liabilities, net of current portion	1,077	1,117
Deferred tax liability	203	203
Total liabilities	154,342	157,326
Stockholders' deficit:
Preferred stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value: 200,000,000 shares authorized; 54,392,170 shares issued and outstanding at March 31, 2024 and December 31, 2023	54	54
Additional paid-in capital	307,042	306,167
Accumulated deficit	(441,787)	(437,406)
Total stockholders' deficit	(134,691)	(131,185)
Total liabilities and stockholders' deficit	$ 19,651	$ 26,141

About Galera Therapeutics Inc

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

CEO	Dr. J. Mel Sorensen M.D.
WEBSITE	galeratx.com
INDUSTRY	Biotechnology
EMPLOYEES	31

Galera Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Galera Therapeutics Inc? What does GRTX stand for in stocks?

GRTX is the stock ticker symbol of Galera Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Galera Therapeutics Inc (GRTX)?

As of Fri May 17 2024, market cap of Galera Therapeutics Inc is 10.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GRTX stock?

You can check GRTX's fair value in chart for subscribers.

What is the fair value of GRTX stock?

You can check GRTX's fair value in chart for subscribers. The fair value of Galera Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Galera Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Galera Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether GRTX is over valued or under valued. Whether Galera Therapeutics Inc is cheap or expensive depends on the assumptions which impact Galera Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GRTX.